Mobi Health News
November 18, 2021
Synthace raises $35M Series C, speeding R&D for drugs and therapeutics

Mobi Health News reports “Synthace raises $35M Series C to accelerate the development of cures and expand reach.” The Synthace Life Sciences R&D Cloud automates data, streamlines insight sharing, and enhances experimentation with machine learning. Using the Synthace platform, scientists can speed up the decision-making process and lower the cost of creating new drugs and therapies—from design to production. 

Guy Levy-Yurista, CEO of Synthace said, “To maximize impact, we need to expand access and reach to customers across the globe—at scale. This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries. With their support, we’ll be able to better deploy human and financial capital to help transform scientific dreams into drugs and alternative food sources.”